All In Biotech

Drug Trial Radar · NCT07641426

A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).

A 2 Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection.

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

58

Planned (sponsor's estimate)

Start

Jun 9, 2026

Primary completion

May 2030

Study completion Dec 2030

Sponsor

Lead sponsor
CASI pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
CASI Pharmaceuticals (China) Co., Ltd.
First posted
Jun 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with with active and chronic active renal allograft antibody mediated rejection (ABMR). The main questions the study aims to answer are:• To evaluate the safety and tolerability of CID-103 in subjects with ABMR with different increasing doses of CID-103.• To evaluate clinical efficacy of CID-103 at an optimal dose in participants with active and chronic active ABMR following renal allograft transplant. The study will be done in two parts: Part A will test increasing doses of CID-103 to see how safe it is and how well people tolerate it. Researchers will also aim to find a safe dose range. Part B will enroll approximately 40 participants to see how well the medicine works and gather more safety and efficacy information. The goal is to find the optimal dose to use in future studies.CID-103 is given through an intravenous (IV) infusion. During the study, participants may receive treatment for up to 12 months, followed by a post-treatment safety follow-up period to check for ongoing safety and effectiveness. This study is an important step toward developing a new treatment for people living with ABMR. If CID-103 is found to be safe and effective, it could offer a new option for patients who do not respond well to current therapies.

Conditions

  • Antibody Mediated Rejection

Interventions

  • CID-103Drug

    Following an initial priming dose of 150 mg on Week 1, participants will receive CID-103 at the higher target dose administered for up to a maximum treatment duration of 49 weeks, in the absence of treatment failure or stopping criteria.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Arms A: Number of participants experiencing study-specific safety events or meeting treatment stopping criteriaTime frame: Up to Week 65
  2. Arms A: Number of participants with AEs with focus on infections, cytopenias, and IRRsTime frame: Up to Week 65
  3. Arms A: Number of Participants With Serious Adverse Events (SAEs)Time frame: Up to Week 65
  4. Arms A: Number of Participants With Anti-Drug Antibody (ADA)Time frame: Up to week 65
  5. Part B: Number of Participants With Achievement of Biopsy-Proven Histologic Resolution of AMR Activity at Week 24Time frame: at Week 24

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital

    Beijing, Beijing Municipality, China · Active not recruiting

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China · Active not recruiting

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • The First Affiliated Hospital of Medical College of Xi'an Jiaotong University

    Xi'an, Shaanxi, China · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.